CNTB Connect Biopharma
- 1.3900
- +0.0200+1.46%
- 1.3700
- -0.0200-1.44%
Connect Biopharma News
Sector Update: Health Care Stocks Retreating Late Afternoon
Health care stocks eased in late Wednesday afternoon trading, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each decreasing 0.1%. The iShares Biotechnology ETF (IBB
Sector Update: Health Care
Health care stocks ease in late Wednesday afternoon trading with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both decreasing 0.1%. The iShares Biotechnology ETF (IBB)
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer
Connect Biopharma (CNTB) is terminating its in-license agreement for CBP-174, an antiallergic, with Pfizer (PFE), effective May, to optimize resources and extend its cash runway The company said Tuesd
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
Connect Biopharma Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
Connect Biopharma Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/17/2024 390.8% HC Wainwright & Co. $7 → $8 Maintains Buy 03/04/2024 329.45% HC Wainwright & Co. → $7 In
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
Connect Biopharma Triumphs With Rademikibart Trials
Connect Biopharma GAAP EPS of -$2.15 Misses by $1.33
Express News | Connect Biopharma Hldgs FY EPS $(1.08) Up From $(2.15) YoY
Express News | Connect Biopharma Holdings : Cash, Cash Equivalents & Short-Term Investments of $118.7 Mln Expected to Support Planned Operations Into at Least 2026
Press Release: Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update -- Reported two positive readouts for rademikibart, the Company's lead asset, from the Global Phase 2b
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company's lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe
Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
MMAT, CNTB and HGAS Among Mid-day Movers
ADRs End Higher; Connect Biopharma Holdings Climbs 21%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed higher on Wednesday, as the S&P/BNY Mellon in
Connect Biopharma to Participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical c
Express News | Connect Biopharma Holdings Shares Are Trading Higher After HC Wainwright & Co Initiated Coverage on the Stock With a Buy Rating and Announced a $7 Price Target
SMR, BBAI and PHUN Are Among Pre Market Gainers
Analysis
Price Target
No Data
